NovaBridge Biosciences (NBP) Equity Ratio (2018 - 2025)

NovaBridge Biosciences (NBP) has 8 years of Equity Ratio data on file, last reported at 0.89 in Q4 2025.

• Quarterly Equity Ratio fell 6.28% year-over-year to 0.89 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.89 (down 6.28% YoY) and the FY2025 annual result came in at 0.89, down 6.28% from the prior year.
• Equity Ratio retreated to 0.89 in Q4 2025 per NBP's latest filing, from 0.93 in the prior quarter.
• Across five years, Equity Ratio topped out at 0.95 in Q2 2025 and bottomed at 0.66 in Q4 2023.
• The 5-year median for Equity Ratio is 0.89 (2021), against an average of 0.85.
• The widest annual swing landed in 2023, when Equity Ratio fell 13.4%; it then surged 43.84% in 2024.
• Tracing NBP's Equity Ratio over 5 years: stood at 0.81 in 2021, then dropped by 12.25% to 0.71 in 2022, then declined by 7.95% to 0.66 in 2023, then surged by 43.84% to 0.95 in 2024, then dropped by 6.28% to 0.89 in 2025.
• Per Business Quant, the three latest NBP Equity Ratio figures stand at 0.89 (Q4 2025), 0.93 (Q3 2025), and 0.95 (Q2 2025).

Peer Comparison